Voya Financial (VOYA) Q3 Earnings and Revenues Top Estimates


On March 14, 2023,
JonesTrading
initiated coverage of Trevi Therapeutics with
a Buy recommendation.

Analyst Price Forecast Suggests 344.89% Upside

As of March 15, 2023,
the average one-year price target for Trevi Therapeutics is $8.36.
The forecasts range from a low of $6.06 to a high of $10.50.
The average price target represents an increase of 344.89% from its latest reported closing price of $1.88.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Trevi Therapeutics
is $0MM.

The projected annual non-GAAP EPS
is -$0.53.

What are Large Shareholders Doing?

NEA Management Company
holds 11,373K shares

representing 18.98% ownership of the company.

No change in the last quarter.

Frazier Life Sciences Management
holds 6,664K shares

representing 11.12% ownership of the company.

In it’s prior filing, the firm reported owning 5,404K shares, representing
an increase
of 18.91%.

The firm

increased

its portfolio allocation in TRVI by 24.78% over the last quarter.

Fairmount Funds Management
holds 5,697K shares

representing 9.51% ownership of the company.

No change in the last quarter.

Rubric Capital Management
holds 5,684K shares

representing 9.49% ownership of the company.

No change in the last quarter.

Viking Global Investors
holds 4,400K shares

representing 7.34% ownership of the company.

No change in the last quarter.

What is the Fund Sentiment?

There are 58 funds or institutions reporting positions in Trevi Therapeutics.

This is a decrease
of
5
owner(s) or 7.94% in the last quarter.

Average portfolio weight of all funds dedicated to TRVI is 0.12%,
an increase
of 18.53%.

Total shares owned by institutions decreased
in the last three months by 6.54% to 43,396K shares.

The put/call ratio of TRVI is 2.07, indicating a

bearish
outlook.

Trevi Therapeutics Background Information
(This description is provided by the company.)

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. Trevi is conducting a Phase 2b/3 clinical trial of Haduvio for the treatment of chronic pruritus associated with prurigo nodularis and a Phase 2 trial for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Trevi is also developing Haduvio for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease and is in the planning stages of a Phase 2 study in this indication. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



Image and article originally from www.nasdaq.com. Read the original article here.

By Fintel